Therapeutic Efficacy of Potent Neutralizing HIV-1-Specific Monoclonal Antibodies in SHIV-Infected Rhesus Monkeys
暂无分享,去创建一个
Michael S. Seaman | Florian Klein | Arup K. Chakraborty | Karthik Shekhar | Jinyan Liu | Dennis R. Burton | Pascal Poignard | Michel C. Nussenzweig | James B. Whitney | Hui-Wen Chang | K. Shekhar | A. Chakraborty | D. Burton | M. Nussenzweig | Mark G. Lewis | P. Poignard | Hui-Wen Chang | D. Barouch | J. Whitney | M. Seaman | K. Stephenson | Thiago Y. Oliveira | E. Borducchi | Kaitlin M. Smith | Jinyan Liu | J. Nkolola | Dan H. Barouch | F. Klein | William J Rinaldi | Erica N. Borducchi | Joseph P. Nkolola | B. Moldt | Brian Moldt | Srisowmya Sanisetty | Crystal Cabral | Stephen Blackmore | Jeffrey Y. Smith | Kathryn E. Stephenson | James R. Perry | Sanjana Gupta | Matthew Beck | William Rinaldi | Crystal Cabral | S. Blackmore | M. Beck | J. Perry | Srisowmya Sanisetty | M. Lewis | Sanjana Gupta | William J. Rinaldi
[1] K. Mansfield,et al. Durable Mucosal Simian Immunodeficiency Virus-Specific Effector Memory T Lymphocyte Responses Elicited by Recombinant Adenovirus Vectors in Rhesus Monkeys , 2011, Journal of Virology.
[2] Florian Klein,et al. Computational analysis of anti–HIV-1 antibody neutralization panel data to identify potential functional epitope residues , 2013, Proceedings of the National Academy of Sciences.
[3] D. Montefiori,et al. Evaluating Neutralizing Antibodies Against HIV, SIV, and SHIV in Luciferase Reporter Gene Assays , 2004, Current protocols in immunology.
[4] Ron Diskin,et al. Increasing the Potency and Breadth of an HIV Antibody by Using Structure-Based Rational Design , 2011, Science.
[5] Ron Diskin,et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice , 2012, Nature.
[6] Jerome H. Kim,et al. Vaccine Protection Against Acquisition of Neutralization-Resistant SIV Challenges in Rhesus Monkeys , 2011, Nature.
[7] Jerome H. Kim,et al. Protective Efficacy of a Global HIV-1 Mosaic Vaccine against Heterologous SHIV Challenges in Rhesus Monkeys , 2013, Cell.
[8] Florian Klein,et al. Antibodies in HIV-1 Vaccine Development and Therapy , 2013, Science.
[9] N. Haigwood,et al. Evidence for Persistent, Occult Infection in Neonatal Macaques following Perinatal Transmission of Simian-Human Immunodeficiency Virus SF162P3 , 2006, Journal of Virology.
[10] Ron Diskin,et al. Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding , 2011, Science.
[11] D R Burton,et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. , 1994, Science.
[12] Ryan McBride,et al. Broadly Neutralizing Antibody PGT121 Allosterically Modulates CD4 Binding via Recognition of the HIV-1 gp120 V3 Base and Multiple Surrounding Glycans , 2013, PLoS pathogens.
[13] J. Brenchley,et al. Generation of the Pathogenic R5-Tropic Simian/Human Immunodeficiency Virus SHIVAD8 by Serial Passaging in Rhesus Macaques , 2010, Journal of Virology.
[14] Young Do Kwon,et al. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9 , 2011, Nature.
[15] Yan Liu,et al. Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120 , 2013, Nature Structural &Molecular Biology.
[16] H. Katinger,et al. Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. , 1999, Immunity.
[17] Michael S. Seaman,et al. Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies , 2012, Proceedings of the National Academy of Sciences.
[18] Pham Phung,et al. Broad neutralization coverage of HIV by multiple highly potent antibodies , 2011, Nature.
[19] K. Mansfield,et al. Magnitude and Phenotype of Cellular Immune Responses Elicited by Recombinant Adenovirus Vectors and Heterologous Prime-Boost Regimens in Rhesus Monkeys , 2008, Journal of Virology.
[20] Tongqing Zhou,et al. Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01 , 2010, Science.
[21] C. Pitcher,et al. Development and Homeostasis of T Cell Memory in Rhesus Macaque1 , 2002, The Journal of Immunology.
[22] M. Lederman,et al. Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248. , 2013, The Journal of infectious diseases.
[23] Mario Roederer,et al. Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1 , 2010, Science.
[24] J. Mascola,et al. Pathogenicity and Mucosal Transmissibility of the R5-Tropic Simian/Human Immunodeficiency Virus SHIVAD8 in Rhesus Macaques: Implications for Use in Vaccine Studies , 2012, Journal of Virology.
[25] A. Trkola,et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies , 2005, Nature Medicine.
[26] Ron Diskin,et al. Restricting HIV-1 pathways for escape using rationally designed anti–HIV-1 antibodies , 2013, The Journal of experimental medicine.
[27] N. Haigwood,et al. Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques , 2010, Nature Medicine.
[28] M. Carrington,et al. Adjunctive Passive Immunotherapy in Human Immunodeficiency Virus Type 1-Infected Individuals Treated with Antiviral Therapy during Acute and Early Infection , 2007, Journal of Virology.
[29] D. Montefiori,et al. Immune Control of an SIV Challenge by a T Cell-Based Vaccine in Rhesus Monkeys , 2008, Nature.
[30] Pham Phung,et al. Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target , 2009, Science.
[31] N. Haigwood,et al. Neutralizing Polyclonal IgG Present during Acute Infection Prevents Rapid Disease Onset in Simian-Human Immunodeficiency Virus SHIVSF162P3-Infected Infant Rhesus Macaques , 2013, Journal of Virology.
[32] N. Haigwood,et al. Macaques Infected with a CCR5-Tropic Simian/Human Immunodeficiency Virus (SHIV) Develop Broadly Reactive Anti-HIV Neutralizing Antibodies , 2007, Journal of Virology.
[33] P. Hraber,et al. T-Cell Vaccination Reduces Simian Immunodeficiency Virus Levels in Semen , 2009, Journal of Virology.
[34] D. Burton,et al. Broadly Neutralizing Antibodies Present New Prospects to Counter Highly Antigenically Diverse Viruses , 2012, Science.
[35] Richard T. Wyatt,et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals , 2009, Nature.
[36] S. Lewin,et al. A novel, rapid method to detect infectious HIV-1 from plasma of persons infected with HIV-1. , 2010, Journal of virological methods.
[37] Rolf Kaiser,et al. HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice , 2013, Proceedings of the National Academy of Sciences.
[38] Baoshan Zhang,et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody , 2012, Nature.
[39] B. Walker,et al. Gag-Specific Cellular Immunity Determines In Vitro Viral Inhibition and In Vivo Virologic Control following Simian Immunodeficiency Virus Challenges of Vaccinated Rhesus Monkeys , 2012, Journal of Virology.